Skip to main content
ACS AuthorChoice logoLink to ACS AuthorChoice
. 2024 Jul 5;10(8):4916–4926. doi: 10.1021/acsbiomaterials.4c00736

Quantifying and Controlling the Proteolytic Degradation of Cell Adhesion Peptides

Samuel J Rozans 1, Abolfazl Salehi Moghaddam 1, Yingjie Wu 1, Kayleigh Atanasoff 1, Liliana Nino 1, Katelyn Dunne 1, E Thomas Pashuck 1,*
PMCID: PMC11322908  PMID: 38968389

Abstract

graphic file with name ab4c00736_0008.jpg

Peptides are widely used within biomaterials to improve cell adhesion, incorporate bioactive ligands, and enable cell-mediated degradation of the matrix. While many of the peptides incorporated into biomaterials are intended to be present throughout the life of the material, their stability is not typically quantified during culture. In this work, we designed a series of peptide libraries containing four different N-terminal peptide functionalizations and three C-terminal functionalizations to better understand how simple modifications can be used to reduce the nonspecific degradation of peptides. We tested these libraries with three cell types commonly used in biomaterials research, including mesenchymal stem/stromal cells (hMSCs), endothelial cells, and macrophages, and quantified how these cell types nonspecifically degraded peptides as a function of terminal amino acid and chemistry. We found that peptides in solution which contained N-terminal amines were almost entirely degraded by 48 h, irrespective of the terminal amino acid, and that degradation occurred even at high peptide concentrations. Peptides with C-terminal carboxylic acids also had significant degradation when cultured with the cells. We found that simple modifications to the termini could significantly reduce or completely abolish nonspecific degradation when soluble peptides were added to cells cultured on tissue culture plastic or within hydrogel matrices, and that functionalizations which mimicked peptide conjugations to hydrogel matrices significantly slowed nonspecific degradation. We also found that there were minimal differences in peptide degradation across cell donors and that sequences mimicking different peptides commonly used to functionalize biomaterials all had significant nonspecific degradation. Finally, we saw that there was a positive trend between RGD stability and hMSC spreading within hydrogels, indicating that improving the stability of peptides within biomaterial matrices may improve the performance of engineered matrices.

Keywords: RGD, exopeptidase, protease, LCMS, bioavailability, biomaterials

Introduction

Hydrogels show great promise for mimicking the extracellular matrix (ECM) that surrounds cells,1 and they are frequently used to expand our understanding of basic physiological processes and to improve the efficacy of regenerative therapies.2 Cells have a dynamic relationship with their microenvironment, and cell behavior within the ECM is influenced by the presence of adhesion domains present in the local matrix.3 Cells actively modulate the local microenvironment by secreting biomolecules, including enzymes, that modify their local niche.4,5 This includes proteases, a class of over 600 enzymes that cleave proteins and peptide bonds.6 Proteases are expressed by all human cell types7 and play important roles in basic physiological processes,6 including cell spreading and migration.8,9 Individual proteases can be highly specific, cleaving only certain peptide sequences, or broadly degrade the termini of proteins or peptides.10

It is well understood that the nonspecific degradation of therapeutic peptide drugs significantly limits their clinical potential.11 However, bioactive peptides are frequently incorporated into biomaterials to better mimic native ECMs,3,12,13 but typically without any characterization of their stability during culture. This includes the canonical RGD cell adhesion peptide14 and also signaling peptides which mimic growth factors, among other sequences.15,16 These peptides are generally intended to be present throughout the lifetime of the material, and any degradation is undesirable and could reduce the efficacy of the biomaterial system. Cell-secreted proteases, such as matrix metalloproteinases (MMPs)17 or cathepsins,18 are often used as stimuli to modify biomaterials.19 However, MMPs and cathepsins are only a fraction of the total number of proteases expressed by cells.7 The enzymes harnessed within bioengineered systems, including MMPs and cathepsins, are almost exclusively endopeptidases,19,20 which cleave the interior of peptides and protein sequences. Exopeptidases, another class of proteases which cleave amino acids at the termini of peptides and proteins (Figure 1A), are ubiquitously expressed in human tissues7 and have been used to tailor the adhesion environment within biomaterials.21 Notably, exopeptidases are believed to be largely responsible for the rapid degradation of peptide drugs,22,23 and modifications to the N-terminus of peptides can slow nonspecific degradation.22,24 Modification of the N-terminus of proteins is widespread, and more than 80% of human proteins have acetylated N-termini.25 The exopeptidase family of proteases includes both aminopeptidases that are active against the N-terminus of peptides and carboxypeptidases that are active against the C-terminus, and the extent to which these classes of proteases degrade peptides is known to be heavily dependent upon the chemistry of the termini.26

Figure 1.

Figure 1

Synthetic scheme to develop design rules to understand the nonspecific degradation of peptides. (A) Proteases can be classified as either endopeptidases, which cleave on the interior of proteins and peptides, or exopeptidases, which cleave terminal amino acids. (B) Peptides were synthesized on a solid-phase resin consisting of microscopic polymer particles functionalized with chemistries that enable the coupling of peptides followed by cleavage from the resin. (C) Peptide synthesis features an iterative process of coupling activated amino acids to the resin, followed by deprotection of the protecting group on the amine terminus of the peptide. (D) Model cell adhesion peptide was split 19 ways during synthesis, and every canonical amino acid except cysteine was added to the N-terminus. The reactions were then pooled together, and the N-terminus was then split again to generate four libraries with different N-terminal modifications, as shown in Table 1. (E) These peptide libraries were incubated with three different cell types, mesenchymal stem cells, endothelial cells, and macrophages, and the extent of peptide degradation was quantified using LCMS.

In this work, we synthesized a series of peptide libraries to better understand how cell-secreted proteases degrade bioactive peptides (Figure 1). Peptide libraries were synthesized with a range of N- and C-terminal modifications to all canonical amino acids except cysteine (Table 1). Peptides with N-terminal amines were rapidly degraded by human mesenchymal stem/stromal cells (hMSCs), human umbilical vein endothelial cells (hUVECs), and proinflammatory macrophages across almost all terminal amino acids. However, simple modifications could significantly reduce this nonspecific degradation across most cell types. These results offer generalized design rules to improve the design and bioactivity of peptide-functionalized hydrogels.

Table 1. Design of N-Terminal and C-Terminal Peptide Librariesa.

graphic file with name ab4c00736_0007.jpg

a

We designed split-and-pool with four different N-terminal modifications and three different C-terminal modifications.

Methods and Materials

Materials

All peptide synthesis reagents were purchased from Chemscene or Ambeed. N,N-Dimethylformamide (DMF), dichloromethane (DCM) (both from VWR BDH Chemicals), piperidine (Millipore Sigma), trifluoroacetic acid (Millipore Sigma), diethyl ether (Fisher Scientific), and N,N-diisopropylethylamine (DIPEA) (VWR) were used as purchased. 20 kDa 8-arm poly(ethylene glycol) dibenzocyclooctyne (PEG-DBCO) was purchased from Biopharm PEG. Batches which dissolved in water in under 30 s were used as received. Otherwise, they were quickly purified by dissolving them in isopropanol and removing impurities using a 10 kDa Amicon centrifugal filter. Approximately 200 mg of PEG was dissolved in 5 mL of isopropanol, and it was centrifuged at 4500 rpm until there was less than one mL of PEG-DBCO/isopropanol left in the filter. This was repeated twice, and then, the filtrate was lyophilized and used.

Methods

Peptide Synthesis Procedure

Peptides were synthesized using standard solid phase-peptide synthesis (SPPS) protocols using either manual synthesis or an automated peptide synthesizer (CEM Liberty Blue) using standard Fmoc-protected amino acids (Chemscene) on a Rink amide resin (Supra Sciences) unless otherwise noted. All amide couplings were done using O-(6-chlorobenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HCTU) in DMF, unless otherwise noted. For each coupling, the amino acid, HCTU, and DIPEA were added in a 4:4:6 molar ratio to the peptide. During peptide synthesis, a ninhydrin test was performed after every addition to test for the presence of free amines. Upon a positive test, the coupling was replicated until it was negative. A capping step was then performed with acetic anhydride (Sigma-Aldrich) in a 10:5:100 acetic anhydride/DIPEA/DMF solution twice for 5 min, and then a ninhydrin test was performed to check for complete capping of the free amines. After successful coupling, the Fmoc group was removed, and the resin was washed with 20% piperidine in DMF twice for 5 min. A ninhydrin test was performed to check for a positive result.

For split-and-pool steps, the resin was washed 3× with DMF, and then the entire amount of resin was weighed on a scale. This number was divided by approximately 22, and this was split 19 ways into 19 separate tubes, with some excess to account for resin loss during transport and weighing. The reactions were performed in 15 mL tubes, and upon successful coupling of all 19 amino acids, all 19 fractions of resin were recombined. Peptide libraries attached to the C-terminal end were completed in one vessel. Peptide libraries attached to the N-terminal end were washed with DMF 3×, weighed, and split four ways, followed by adding the desired chain-end chemistry. Once the N-terminal libraries were split four ways, they were not recombined again. Peptides with C-terminal carboxylic acids were synthesized using 2-chlorotrityl chloride resin. For the COOH library, 2 mmol of resin was weighed out, and 52.6 μmol of each amino acid (1 mmol total synthesis scale) was added into a single 50 mL tube. 25 mL of DCM was added, and then, DMF was added dropwise until all of the amino acids went fully into solution. The 2-chlorotrityl chloride resin was washed with DCM for five min to swell the resin, at which time the DCM was drained, and the amino acid solution was added with 5 equiv of DIPEA. After 30 min another 1.5 equiv of DIPEA was added. After another 30 min 5 mL of methanol was added to cap the resin, at which time the Fmoc groups were deprotected and the peptides were synthesized using standard Fmoc-peptide synthesis procedures.

Peptide libraries and all peptides containing tryptophan were cleaved using 92.5% trifluoroacetic acid (TFA), 2.5% H2O, 2.5% triisopropylsilane (TIPS), and 2.5% dithiothreitol (DTT). Peptides which lacked tryptophan were cleaved without DTT. Peptides were typically cleaved for 2–3 h at room temperature using approximately 25 mL of cleavage solution per mM of peptide. However, peptides containing azides were cleaved for 30 min to prevent degradation of the azide group. The masses of the peptide libraries were checked using liquid chromatography mass spectrometry (LCMS), and if protecting groups remained, the peptides were recleaved for 30 min. At the end of the cleavage, the peptides were precipitated in diethyl ether. These were then centrifuged for 5 min at 4000 rpm, and the supernatant was discarded. The peptide pellet was washed with diethyl ether and centrifuged, and this was repeated twice. The peptide pellet was allowed to dry, then dissolved in water and neutralized with ammonium hydroxide prior to purification.

The cyclic RGD peptide was synthesized on a 2-chlorotrityl chloride resin. The first amino acid (0.3 mmol of amino acid per gram of resin) was dissolved in DCM and added to the resin in a shaker vessel. Five equivalents of DIPEA were then added, and after 5 min of shaking, another 1.5 equiv of DIPEA was added. After 1 h, the unreacted 2-chlorotrityl chloride resin was capped with an excess of methanol for 30 min with another five equiv of DIPEA. The rest of the amino acids were then coupled using standard solid-phase Fmoc-synthesis protocols. After the last Fmoc group was deprotected, the resin was washed 3× in DMF and 3× in DCM. The peptide was then cleaved under mild acidic conditions consisting of 5% trifluoroacetic acid and 2.5% triisopropylsilane in DCM. The mild cleavage solution was added to the resin for 5 min and then collected into a round-bottom flask, and this was repeated until the resin turned dark red or black. The collected liquid was then precipitated in ether. This cyclization was then dissolved in 50:50 acetonitrile/water, neutralized with 1 M NH4OH, and lyophilized. The protected linear NH2-GRGDSK(N3)–OH peptide was then cyclized. This was done by dissolving the peptide into DMF at 1 mg/mL and adding 3 equiv of (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]-pyridinium 3-oxid hexafluorophosphate) (HATU) and 3 equiv of DIPEA. After 6 h, the DMF was removed using rotary evaporation at 65 °C.

The PanMMP cross-linking peptide was functionalized with 2-azido acetic acid on the N-terminus. 2-Azido acetic acid was synthesized by mixing bromoacetic acid (70.168 g, 505 mmol), sodium azide (32.504 g, 500 mmol), and water (250 mL); the solution was stirred overnight at RT under ambient conditions. The next day, the solution was acidified to pH ∼ 1 using hydrochloric acid and extracted using ethyl acetate (5 × 100 mL). The organic layers were combined and dried in vacuo to afford the 2-azidoacetic acid as a colorless liquid. 2-Azidoacetic acid was stored in a −20 °C freezer until it was needed for synthesis.

All peptides were purified using HPLC using a Phenomenex Gemini 5 μm NX-C18 110 Å LC Column 150 × 21.2 mm. Gradients were run from 95% mobile phase A (water with 0.1% TFA) and 5% mobile phase B (acetonitrile with 0.1% TFA) to 100% mobile phase B. A typical HPLC run featured a two min equilibration step, followed by a 10 min ramp from 95% mobile phase A to 100% mobile phase B, and then two min of equilibration at 100% mobile phase B before ramping back down to the starting conditions. Notably, the split-and-pool libraries were ramped up to 100% mobile phase B over two min since these libraries consisted of approximately 19 different peptides, which were not intended to be separated from each other. The protected cyclic RGD peptides were purified using a gradient that ramped from 30% mobile phase B to 100% mobile phase B. After purification, all peptides were lyophilized and ready to use, except for the protected cyclic RGD peptide, which was deprotected using 95% TFA, 2.5% TIPS, and 2.5% H2O for 1 h.

PEGylated RGEFV peptides were prepared using standard SPPS, as described above. Immediately adjacent to the chain-end chemistry of interest, on the N or C terminus of the peptide, a Fmoc-Azidolysine–OH (AR001RXM, Aaron Chemicals) was added. Once seven variations of the azidolysine functionalized peptides were synthesized, HPLC-purified, dissolved in water at 10 mM, verified via LCMS, and 20 mg of peptide was transferred to new Eppendorf tubes. 100 mg of m-dPEG12-DBCO (QBD-10596, Vector Laboratories) was dissolved in water and evenly distributed 7 ways among all azide-functionalized RGEFV peptides. The strained alkyne was allowed to click onto the azide-functionalized peptides overnight. The next day, PEGylated peptides were HPLC-purified, validated via LCMS, and lyophilized until needed.

Peptide Degradation Studies

hUVECs on Tissue Culture Plastic

hUVECs (Lifecell Technology) at passage 2 were seeded into 24 well plates at a seeding density of 150 000 cells per well in 1 mL of expansion media (Lifeline Cell Technology, LM-0002) containing ascorbic acid, hydrocortisone, fetal bovine serum (FBS), l-glutamine, rh-EGF, heparin, and EnGS-US (all supplements LifeFactors, LS-1122). After 24 h, the media was changed. After 24 hours of culture the peptide libraries, each containing 19 peptides and the nonproteolytically degradable NH2-βFβAβAβAβAβA-NH2 internal standard, where βA is β-alanine, and βF is β-homophenylalanine, were added to the cell media for a final concentration of 37 μM per peptide. Each library was tested in triplicate per cell type per study. 40 μL samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points, samples were frozen −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS. The following donors were used for these studies: lot 08119 from a Caucasian male, lot 08478 from a Caucasian/African American female, and lot 04608 from an African American male. Initial degradation studies with cells on tissue culture plastic (TCP) were done using all three donors, and subsequent studies were done using lot 04608.

hMSCs on TCP

hMSCs (Rooster Bio) at passage 3 were seeded into 24 well plates at a seeding density of 75 000 cells per well in 1 mL of RoosterBasal-MSC–CC (RoosterBio, SU-022) containing RoosterBooster-MSC (RoosterBio SU-003). After 24 h, the medium was changed, and and after 24 hours of culture the peptide libraries were added to the cell medium for a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate per cell lot, for a total of 63 wells. 40 μL samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points, samples were frozen −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS. The following donors were used for these studies: lot 310264 was a 20 year old African-American male, lot 310268 was a 19 year old Eritrean/east African female, and lot 210280 was a 26 year old Asian male. Initial degradation studies with cells on TCP were performed using all three donors, and subsequent studies were done using lot 310268.

Peripheral Blood Mononuclear Cells Derived Macrophages on TCP

Peripheral blood mononuclear cells (PBMCs) were purchased from AllCells and placed in a 24 well plate with a seeding density of one million cells per well using RPMI (Cytiva, SJ30027.1) containing 10% FBS (Foundation Fetal Bovine Serum, Gemini Bioproducts) and 1% antibiotic–antimycotic (Gibco, 15240–062). Human M-CSF (Peprotech, 300–25–50UG) was immediately added at a concentration of 20 ng/mL for 5 days to induce differentiation in M0 macrophages. After day 5, the media was changed to RPMI containing interferon gamma (IFN-γ) (Peprotech, 300–02–20UG), and 100 ng/mL lipopolysaccharide (LPS) (Sigma L4391–1MG) and allowed to polarize for 3 days (Day 8 of culture). On day 9, the medium was changed to macrophage serum-free medium with l-glutamine (Gibco 12065–074). Peptide libraries were added 24 h later to the cell media for a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate per cell lot, for a total of 63 wells. 40 μL samples were collected from the media at 0, 1, 4, 8, 24, and 48 h. In-between time points, samples were frozen −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS. Three donors and one cell line were used for these studies. The donors came from lot 3087423 a 26 year-old Asian male, lot 3088202 a 52 year-old White male, and lot 3091412 a 21 year-old African-American female. The primary PBMC-derived macrophages were used for initial studies of TCP.

THP-1-Derived Macrophages on TCP

THP-1 cells were placed into a 24 well plate with a seeding density of one million cells per well using RPMI (Cytiva, SJ30027.1) containing 10% FBS and 1% anti–anti, with PMA at a concentration of 100 ng/mL for 2 days. After day 2 the medium was changed to RPMI containing IFN-γ, 20 ng/mL MCSF, and 100 ng/mL LPS and allowed to polarize for 3 days (day 5 of culture). After 6 days the media was changed to macrophage serum-free media with l-glutamine (Gibco 12065–074) peptide libraries were added 24 h later to the cell media for a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate, for a total of 21 wells. 40 μL samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points, samples were frozen at −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS. The THP-1 cell line was used for initial degradation experiments on TCP and all other cell studies.

hUVECs in PEG

hUVECs at passage 2 were seeded into T-75 flasks in basal media (Lifeline Cell Technology, LM-0002) containing ascorbic acid, hydrocortisone, FBS, l-glutamine, rh EGF, heparin, and EnGS-US (all supplements, LifeFactors, LS-1122) until they were 80–90% confluent. Cells were then washed with PBS and trypsinized with 2 mL of 0.25% trypsin in Hank’s buffered salt solution with ethylenediaminetetraacetic acid (EDTA) (Cytiva, SH30042.01) and incubated for 5 min. Once cells have detached, they are centrifuged at 0.2 RCF for 5 min and counted using a hemocytometer. At this time, they were seeded into 28 μL of 3.5% (W/V) 8-arm-PEG-DBCO (MW 20 000 kDa) hydrogels at a density of 150 000 cells per gel, with 35% of the PEG arms cross-linked with the PanMMP peptide N3KGPQGIWGQKK(N3), and 10% of the arms tethered with cyclic GRGDSK(N3) using copper-free click chemistry of the strained alkyne DBCO with the azides. After 24 h peptide libraries were added to the cell media at a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate, for a total of 21 wells. 40 μL samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points samples were frozen −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS.

hMSCs in PEG

hMSCs at passage 3 were seeded into T-75 flasks until they were 80–90% confluent. Cells were then washed with PBS and trypsinized in 2 mL of trypsin and incubated for 5 min. Once cells have detached they were centrifuged at 0.2 RCF for 5 min and counted using a hemocytometer. At this time, they were seeded into 28 μL of 3.5% (W/V) 8-arm-peg-DBCO (MW 20 000 kDa) hydrogels at a density of 75 000 cells per gel with 35% of PEG arms cross-linked with a PanMMP peptide N3KGPQGIWGQKK(N3), and 10% of the arms are tethered with cyclic GRGDSK(N3) using copper free click chemistry of the strained alkyne DBCO with the azides. After 24 h peptide libraries were added to the cell media for a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate for a total of 21 wells per study. 40 μL samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points samples were frozen −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS.

THP-1-Derived Macrophages in PEG

THP-1 cells were placed into untreated six well plates with RPMI (Cytiva, SJ30027.1) containing 10% FBS and 1% anti–anti, with PMA at a concentration of 100 ng/mL for 2 days. After day 2, the media was changed to RPMI containing IFN-γ, MCSF, and LPS and allowed to polarize for 3 days (day 5 of culture). On day six, the medium was changed to fresh RPMI and detached using a cell scraper. They were then centrifuged at 0.2 RCF for 5 min, counted using a hemocytometer and seeded into 40 μL gels at a density of 1million cells per gel containing 28 μL of 3.5% (W/V) 8-arm-PEG-DBCO (MW 20 000 kDa) hydrogels at a density of 75 000 cells per gel with 35% of PEG arms cross-linked with a PanMMP-sensitive peptide N3KGPQGIWGQKK(N3), and 10% of the arms are tethered with cyclic GRGDSK(N3) using copper-free click chemistry of the strained alkyne DBCO with the azides. After 24 h, peptide libraries were added to the cell media for a final concentration of 37 μM per peptide. Each library was tested simultaneously, in triplicate, for a total of 21 wells. 40 samples were collected from the media at hours 0, 1, 4, 8, 24, and 48. In-between time points, samples were frozen at −80 °C. After 48 h, samples were kept frozen and thawed just prior to LCMS.

LCMS Data Acquisition and Analysis

4 μL of neat acetic acid was added to each well immediately after the plates were removed from the −80 °C freezer to acidify the media and prevent further peptide degradation by proteases. From each sample, 10 μL of crude solution was introduced by the LC–MS through an Thermo Scientific Vanquish LC System (Thermo Fisher Scientific), which was outputted to a Thermo Scientific LTQ XL Linear Ion Trap Mass Spectrometer (Thermo Fisher Scientific). The sampled mixture was trapped on a column (ProntoSIL C18 AQ, 120 Å, 3 μm, 2.0 mm × 50 mm HPLC Column, PN 0502F184PS030, MAC-MOD Analytical Inc.). The samples were loaded onto the column with a solvent containing acetonitrile/water, 5:95 (v/v) containing 1% acetic acid at a flow rate of 300 μL/min and held for 1 min. The sample was then eluted from the column with a linear gradient of 5–40% Solvent B (1% acetic acid in acetonitrile) at the same flow rate for 5 min. This was followed by a 1 min ramp up to 100% Solvent B, where it was re-equilibrated with Solvent A (1% acetic acid) to 5% solvent B over the course of 1 min and held there for 2 min. The column temperature was constant at 29 °C. The mass spectrometer was operated in the positive ion mode. Using a heated ESI, the source voltage was set to 4.1 kV, and the capillary temperature was 350 °C.

Data analysis was performed on an Xcalibur Software (Thermo Scientific). Peptides were identified automatically using the Thermo Xcalibur Processing Setup window, where the mass (m/z) ± 0.5 atomic mass units and expected retention times for each quantified peptide were input. This was later used to isolate individual peptide species from the total ion count trace using the Thermo Xcalibur Quan Setup window, where the area under the curve was calculated and visually inspected for accuracy. All peptides were normalized to a non-degradable internal standard, NH2-βFβAβAβAβAβA-NH2. The integrated peak area of the peptide of interest was divided by the NH2-βFβAβAβAβAβA-NH2 internal standard to create an area ratio. Relative amounts of a peptide were then calculated by normalizing all values to their corresponding time zero area ratio. Calculated data was visualized using RStudio.

Viability Assay

Cells were cultured in gels, as described. A working solution was made by diluting the alamarBlue dye (Y00–100, Thermo Scientific) (1:10) with the same media in which cells were cultured in. The medium the cells were in was replaced with 1 mL of working solution. 1 mL of working solution was also placed into 3 blank wells. The cells were then placed in the incubator at 36 °C, 5% CO2 for 3 h. After 3 h, 100 μL of the solution was sampled and placed into a 96 well plate, and fluorescence intensity was measured using a Tecan plate reader using 560Ex/590Em nm filter settings, reading from the bottom of the plate. Immediately after measurement, the Alamar Blue working solution was washed three times with appropriate media for each cell type being measured and placed back in the incubator. The same cells were used for each measurement during Days 0, 3, and 7.

DNA Quantification Assay

Cells were cultured in gels as described above. However, gels were placed on SilGuard-coated 24 well plates to prevent cell adhesion to the TCP, ensuring the origin of the quantified DNA is exclusively taken from cells located within the gels. To coat plates with Sylgard, the Sylgard 184 elastomer was mixed with its curing agent in a 1:10 ratio. Subsequently, the mixture was poured into each well of a 24-well plate. The elastomer was allowed to cure at room temperature overnight for all of the experiments. Following the curing process, an alcohol-based reagent was applied through spraying, and the samples were subjected to UV sterilization for 24 h.

A two-step procedure was used to quantify the double-stranded DNA (dsDNA): (1) sample homogenization and (2) dsDNA quantification. Sample homogenization was performed via enzymatic digestion of the gel and cellular components using papain (P4762–50 mg, Sigma-Aldrich). Papain was reconstituted to a concentration of 10 mg/mL using PBS, 300 μL was aliquoted into Eppendorf tubes, and the papain stock solution was stored at −20 °C until needed. l-cysteine (25–7210–00, Chemical Dynamics Co.) was prepared at a concentration of 24.2 mg/mL in DI water, placed into 0.5 mL aliquots, and stored at −20 °C until use. EDTA was prepared into a stock of 0.333 M in DI water and stored at 4 °C in the fridge until needed (shelf life 3 months). Papain solution was prepared fresh just prior to homogenization by combining and diluting papain, l-cysteine, and EDTA to a final concentration of 125 μg/mL, 0.242 mg/mL, and 0.333 M, respectively, with PBS. 300 μL of papain digestion solution was used per 28 μL of gel. Each gel was then incubated overnight at 4 °C. The next day, homogenization was verified by pipetting samples up and down, noting the absence of cross-linked gel material.

Double Stranded DNA was quantified using the Quantifluor dsDNA System (E2670, Promega). 1× TE buffer was prepared by diluting the stock TE buffer 20-fold with microbial cell culture grade water (BP2820–100, Fisher BioReagents). The Quantifluor dsDNA dye was then diluted 400 fold with 1× TE buffer to create the working dye solution. 200 μL. A standard curve was prepared in a 96-well plate by placing 2 μL of DNA standard into 200 μL of the working dye solution for a total amount of 200 ng of dsDNA standard. Then, a 1:4 dilution series was performed down to 0.05 ng of dsDNA standard using the working dye solution as the diluent and a blank containing just 2 μL of 1× TE buffer in the working dye solution. This was performed in triplicate. 15 μL of the homogenized samples were placed into an empty well of the plate, and 185 μL of the working dye solution was added on top of the unknown samples. Samples were protected from light and incubated for 5–10 min, and the fluorescence (504 nmEx/531 nmEm) was measured using a plate reader (SpectraMax iD3, Molecular Devices). The three standard curves were averaged and then used to calculate the total dsDNA present within each sample.

Actin Staining

Cells in gels were cultured as described above, washed two times with 1× PBS, stained in 10% neutral buffered formalin (NBF) for 15 min, and washed three times with 1× PBS. Cells were then permeabilized with 100% methanol at 4 °C for 30 min, washed two times with 1× PBS, and permeabilized with 0.5% Trition X-100 for 15 min at RT. Gels were washed two times with 1× PBS and blocked using blocking solution (1% BSA, 0.3 M glycine, and 0.01% Triton X-100) for 1 h. Cells were then incubated with antipan actin mouse monoclonal antibody (AANO2, Cytoskeleton inc.) (1:500) in blocking solution and agitated overnight at 4 °C. Gels were washed with 0.1% Triton X-100 in 1× PBS and then three times with 1× PBS. Cells were then incubated with goat antimouse IgG2b-AF555 (1091–32, SouthernBiotech) (1:400) in blocking solution for 60 min at RT in the dark. Gels were washed three times with 1X PBS and then incubated in DAPI (Anaspec AS-83210) (1:10 000) in 1× PBS for 20 min at RT. Cells were mounted on coverslips just prior to imaging. Cells were imaged using confocal microscopy (Nikon Eclipse Ti). Cell area was quantified by first importing a Z-stack into the FIJI distribution of ImageJ2. The Z-stack was then projected into two-dimensional space using the maximum projection function. After splitting the color channels, the threshold was adjusted such that only DAPI or phalloidin staining was applied. Last, the “analyze particles” function was applied to gain two pieces of information: (1) the number of particles taken from the DAPI channel and the total particle area taken from the phalloidin area. Should two nuclei be very close and count as one particle, the particle count was adjusted manually for accuracy. The total particle area was then normalized to the number of particles to obtain an average area per cell. Each group tested was done using three replicates, each done in triplicate.

Statistical Analysis

Statistical analysis was done using multiway analysis of variance (ANOVA) with a Tukey posthoc test. All comparisons in this manuscript are statistically significant (p < 0.05), unless otherwise noted. Statistical data can be found in Figure S24.

Results and Discussion

Design and Synthesis of Peptide Libraries to Quantify Nonspecific Peptide Degradation

There are dozens of human exopeptidases,27,28 and the activity of each protease is typically dependent on the amino acid at the termini of the peptide.29 Significant effort has gone into preventing the degradation of therapeutic proteins, and modification of the N-terminal amine or C-terminal carboxylic acid or inclusion of β-amino acids frequently reduces nonspecific peptide degradation.24,30,31 While most work assess the proteolytic degradation of peptides has focused on the substrate preferences for individual proteases,32 or degradation of specific peptides,33 we set out to better understand peptide degradation due to the total protease expression of entire cell types across a range of terminal chemistries. In order to characterize the effects of nonspecific proteolytic degradation as a function of end group, we designed a series of RGEFV peptide libraries based upon the widely used RGD peptide. Seven peptide libraries were synthesized (Table 1), each having a different terminal chemistry and containing 19 of the 20 canonical amino acids (excluding cysteine), to quantify peptide degradation by cell type. The aspartic acid (D) on the RGD was mutated to glutamic acid (E) to prevent the peptides from binding cell–surface integrins while retaining their physiochemical properties34 and also included a hydrophobic Phe–Val utilized in the RGDFV adhesion peptide35 to improve chromatographic retention during analysis.

Peptides were synthesized by using standard solid-phase peptide synthesis techniques (Figure 1B,C). We utilized a split-and-pool peptide synthesis technique to build the libraries.36 This was done by splitting the resin equally into 19 different vials at the desired synthesis step, followed by the addition of a different amino acid to each of the 19 vials (Figure 1D). Upon completion of the coupling steps, the 19 resins were then recombined into a single batch for further synthesis. For the N-terminal libraries, split-and-pool synthesis was performed on the N-terminal side of the RGEFV peptide. The N-terminal library resin was split again to make four different 19-peptide libraries with different N-terminal modifications. These N-terminal chemistries are an amine (NH2), an acetyl (Ac), an N-terminal β-alanine (N-βA), and an N-terminal acetylated β-alanine (Ac-βA). For the C-terminal libraries, the split-and-pool was performed on the C-terminal side of the RGEFV peptide with one of three C-terminal chemistries: a C-terminal carboxylic acid (COOH), a C-terminal amide (Am), or a C-terminal amidated β-alanine (C-βA). Peptide libraries were added to the cell culture media and analyzed by LCMS (Figure 1E). All N-terminal libraries had an amidated C-terminal β-alanine, and all C-terminal libraries had an acetylated β-alanine on the N-terminus.

Quantification of Peptide Degradation by Cells

Each of the seven peptide libraries was added to the cell culture media of three cell types commonly used in biomedical research: hMSCs, hUVECs, and classically polarized macrophages (Macrophages) cultured on TCP. Samples of each peptide library were taken in cell culture media at 0, 1, 4, 8, 24, and 48 h, acidified with acetic acid to prevent further enzymatic degradation, and quantified using LCMS. The extent of degradation was determined by calculating the ratio of peptide found at later time points to the zero hour time point (Figure 2). While peptides with 19 different terminal amino acids were present in every library, isoleucine and leucine have identical masses and were combined for analysis. It should be noted that any chemical modification to the peptide that changes the mass of the peptide will reduce the intensity of the peptide peak in mass spectrometry. While our data suggest that a significant fraction of degradation is due to exopeptidase activity, it is possible and even likely that endopeptidases or other enzymes are also degrading these peptides.

Figure 2.

Figure 2

Nonspecific degradation of peptides depends on cell type and the chemistry of peptide termini. Peptide libraries were incubated with three different cell types for 48 h, and the fraction of peptides remaining was quantified. Notably, peptides with N-terminal amines (NH2) were almost completely degraded, irrespective of the N-terminal amino acid while adding a β-amino acid to the C-terminus of the peptide (C-βA) or an acetylated β-amino acid to the N-terminus (Ac-βA) significantly reduced degradation.

Our results show that nonspecific degradation is primarily controlled by the chemistry of the peptide termini and that simple modifications can drastically reduce peptide degradation (Figures 3 and S1). The amino acids present at the termini influenced how quickly a peptide was degraded, but the difference between amino acids was much smaller than terminal chemistries. Peptides with N-terminal amines were rapidly degraded for almost every amino acid by all three cell types. In hMSCs after 8 h in culture, 15 of the 18 peptides with N-terminal amines (NH2) had less than 50% of the peptide remaining, 13 peptides had less than 25% remaining, and 9 peptides had less than 5% of the original peptide remaining. hUVECs demonstrated less degradation of NH2 peptides, but 13 peptides had less than 50% remaining after 8 h, and 9 peptides had less than 25% remaining. Macrophages had the least degradation, but nine of the 18 peptides had less than 50% remaining after 8 h in culture. For all cell types, modifications of the N-terminus reduced peptide degradation, although they had different levels of efficacy in preventing degradation. While peptides with N-terminal β-alanines (N-βA) were completely degraded by 48 h when cultured with hMSCs, 42% of N-βA peptides remained after eight h versus 17% for peptides with N-terminal amines, suggesting that the N-βA does slow down degradation in hMSCs. N-βA modification was more effective at inhibiting peptide degradation in hUVECs, which increased the fraction of peptides remaining after 48 h from 7% in NH2 to 58% in N-βA, and macrophages, which went from 25% remaining for NH2 to over 90% for N-βA.

Figure 3.

Figure 3

Nonspecific degradation of peptides with N-terminal amines across three different cell types. The amount of degradation at different time points was quantified. Averaging over all amino acids quantified the effects of N-terminal modifications for (A) hMSCs, (B) hUVECs, and (C) macrophages and C-terminal modifications for (D) hMSCs, (E) hUVECs, and (F) macrophages. Error bars represent the standard deviations across all terminal amino acids.

The positive charge of the N-terminal amine can play a role in aminopeptidase recognition of the peptide substrate.37 Both the NH2 and N-βA termini are positively charged, and the uncharged acetylation (Ac) and acetylated β-alanines (Ac-βA) were more effective at preventing degradation. There was almost complete degradation of all peptides with N-terminal amines or N-terminal β-alanines when cultured with hMSCs on TCP, but removing the charge on the N-terminus was effective at slowing degradation, and 10% of acetylated peptides and 37% of Ac-βA peptides were still present after 48 hours. For hUVECs, 82% of acetylated peptides and 78% of peptides with acetylated β-alanines remained, and for macrophages, approximately 91% of peptides remained for both Ac and Ac-βA.

The chemistry of the C-terminus also had a significant effect on peptide degradation, although to a lesser extent than the chemistry of the N-terminus. Peptides with C-terminal carboxylic acids typically had the most degradation, with hUVECs having the most degradation, with 19% remaining, followed by hMSCs (21%) and macrophages (59%). Modification of the C-terminus reduced the level of degradation for all cell types.

C-terminal amidation and an amidated C-terminal β-alanine both had 31% of peptide remaining after 48 h for hMSCs. However, C-βA modification was superior to C-terminal amidation in preventing peptide degradation of hUVECs (85% remaining in C-βA versus 59% in Am) and macrophages (99% remaining in C-βA versus 90% for Am) than peptides which had C-terminal amides, and those with C-terminal β-alanines had the least. Current strategies to prevent exopeptidase degradation of peptides are largely focused on non-natural amino acids or acetylation of the N-terminus. Peptides with N-terminal acetylated β-alanines and C-terminal amidated β-alanines would largely have reduced degradation compared to existing strategies for all cell types. Acetylated N-terminal β-alanines result in reduced degradation compared with standard acetylation for hMSCs, and amidated C-terminal β-alanines have significantly reduced degradation for hUVECs and macrophages. Globally, peptide degradation varied by cell type, and across all peptides, hMSCs had more degradation than hUVECs, which had more degradation of macrophages for every end group at 24 and 48 h, apart from the C-terminal carboxylic acid, which was more degraded at 48 h by hUVECs than hMSCs.

We tested the peptide libraries with three different donors for each cell type, including both sexes and multiple ethnicities, to ensure that the results were robust across biological variation. We found that the trends for degradation across different chemistries and amino acids were similar across donors for all three cell types, and typically, there was less than a 10% difference in degradation rate across all amino acids between donors. Averaging across all end groups and amino acids, after 48 h, there was between 54 and 59% of peptide remaining across the three hUVEC donors, 13 and 22% across the three hMSC donors, and 76 to 84% for the three macrophage donors (Figures S2–S4). Additionally, the THP-1 monocyte cell line had 70% of the peptides remaining across all conditions, and the pattern of degradation across end groups and amino acids closely matched the human primary cells.

The split-and-pool libraries contain 19 different peptides each at a 37 μM concentration, while most biomaterials are functionalized by a single peptide at a higher concentration. We performed degradation studies using an individual peptide with a glycine at the terminus at concentrations ranging from 19.5 to 5000 μM. We broadly saw that peptides at lower concentrations were more rapidly degraded than peptides at higher concentrations (Figures 4 and S5). The effects of terminal chemistry on peptide degradation were largely conserved across concentration ranges, with peptides having N-terminal amines being rapidly degraded even at 5 mM concentrations. After 48 h only 5% of amine-terminated RGEFV peptides remained after starting with an initial concentration of 5000 μM. C-terminal degradation could also be rapid, and only 26% of the initial peptide remained of an initial 5000 μM COOH peptide when cultured with hUVECs (Figure S5). Overall, these results indicate that increasing peptide concentration leads to higher amounts of peptide at later time points, but modifying the chemistry at the terminus is the most effective method for increasing the concentration of peptide after 48 h.

Figure 4.

Figure 4

Nonspecific degradation of peptides with N-terminal amines is rapid across peptide sequences and for cells in hydrogels. (A) Degradation of peptides with N-terminal amines can be rapid even at 5 molar peptide concentrations. (B) Scrambled version of the TGF-β1 mimicking the LIANAK peptide was rapidly degraded by hUVECs when the peptide feature an N-terminal amine or C-terminal carboxylic acid. (C) hUVECs cultured in PEG hydrogels rapidly degrade RGEFV peptides with free N-terminal amines or C-terminal carboxylic acids.

Our initial libraries were derivatives of an RGEFV peptide based on the RGD cell adhesion peptide. To ensure that the results are not specific to this sequence, we synthesized two other peptides, an IVKVA peptide based upon the IKVAV laminin-mimetic peptide,38 and an LIAANK based upon the LIANAK TGF-β mimetic peptide.39 We made peptides with each of the terminal chemistries having glycine at the terminus since it both does not have any special chemical groups and has degradation in the RGEFV peptides near the average for each condition (Figures 4B and S6). We found that the same broad trends held, with most peptides having more C-terminal degradation in the COOH condition, and acetylating the N-terminus, either Ac or Ac-βA reduced N-terminal degradation.

Peptide Degradation by Cells in Hydrogels

The overall goal of this work is to understand how cells in hydrogel scaffolds degrade peptides. Since cell spreading and migration often involve proteases in vivo, we cultured hMSCs, hUVECs, and macrophages within protease-substrate peptide cross-linked 8-arm poly(ethylene glycol) (PEG) hydrogels. We found that peptide degradation with hUVECs was similar between TCP (Figure 2) and within the hydrogels (Figure 4B). Macrophages also had similar peptide degradation kinetics when soluble peptides were added to cells on TCP or cells in gels. Interestingly, hMSCs had significantly less nonspecific degradation of peptides when cultured in gels (Figure S6) compared to cells cultured on TCP (Figure 2). While acetylation of the N-terminus was largely effective at reducing nonspecific degradation, peptides with an N-terminal histidine were an exception, and peptides with an acetylated histidine were cleaved for all three cell types when cultured in gels (Figures 4, S7). Overall, the same broad peptide degradation trends held for cells in gels, with N-terminal amines undergoing significant degradation for all three cell types versus other N-terminal functionalizations and C-terminal carboxylic acids being significantly degraded by hMSCs and hUVECs compared to other terminal chemistries (Table 2, Figure S7). Macrophages cultured on TCP had significantly reduced degradation of C-terminal libraries compared to the two other cell types (Figures 2, 3) but still only had 59% of peptides remaining after 24 h across amino acids. However, macrophages encapsulated in hydrogels had greater than 96% remaining of all C-terminal peptide chemistries after 48 h in culture (Table 2).

Table 2. Quantifying the Degradation of Peptide Libraries after 48 h in Culture with Cells Encapsulated in PEG Hydrogelsa.

terminal chemistry cell type fraction remaining standard deviation
Ac-βA hMSC 0.81 0.12
  hUVEC 0.90 0.10
  macrophage 0.99 0.03
Ac hMSC 0.82 0.15
  hUVEC 0.90 0.18
  macrophage 0.87 0.20
N-βA hMSC 0.62 0.17
  hUVEC 0.76 0.14
  macrophage 0.95 0.06
NH2 hMSC 0.20 0.23
  hUVEC 0.19 0.22
  macrophage 0.13 0.25
C-βA hMSC 0.83 0.07
  hUVEC 0.99 0.08
  macrophage 0.98 0.03
Am hMSC 0.73 0.11
  hUVEC 0.75 0.17
  macrophage 0.98 0.03
COOH hMSC 0.36 0.15
  hUVEC 0.25 0.20
  macrophage 0.96 0.04
a

Each value is the average across 19 amino acids.

While the effects of the N-terminal and C-terminal amino acids tended to be much smaller than the chemistry of the termini, there were some trends seen across cell types in both the cells on TCP and cells encapsulated within PEG hydrogels. The presence of positively charged amino acids (lysine and arginine) on the N-terminus of the peptide increased the degradation rate, and tryptophan also degraded more rapidly across all N-terminal chemistries. Interestingly, proline slowed down degradation for N-terminal amines but increased degradation for N-terminal β-alanines. For N-terminal amines, the presence of negatively charged amino acids (glutamic acid or aspartic acid) reduced degradation rates. While acetylation was typically effective in preventing nonspecific degradation of cells in gels, histidine was a significant exception and was substantially degraded by all three cell types. On the C-terminus, tryptophan increased the rate of degradation across all chemistries, alanine, phenylalanine, lysine, and tyrosine had increased degradation for the carboxylic acid library, and aspartic acid, glutamic acid, and valine had decreased degradation.

Effects of Peptide Conjugation on Degradation

In addition to their roles as adhesion ligands or growth factor mimetic peptides, peptides are also widely used to cross-link hydrogel matrices.17,40 This is often done by utilizing chemistries that can react with canonical amino acids, such as thiol–maleimide reactions,41 or incorporating non-natural chemistries into the peptide side chain, such as azides, which can then undergo click reactions with reactive groups present on polymers.42 To better understand how these peptide modifications influence degradation kinetics, we synthesized a series of peptides and put an azido-lysine on either the N-terminus or C-terminus and then functionalized the termini with each of the seven different terminal chemistries (Figure 5). A portion of these peptides were then functionalized with a (PEG)12 chain modified with a DBCO group that is commonly used in biomaterial synthesis. We added both the azide-containing peptides and PEG-modified peptides to cell culture media and quantified degradation by hMSCs, hUVECs, and macrophages (Figures 5 and S8). We found that PEG modification slows peptide degradation for all N-terminal and C-terminal chemistry across hMSCs, hUVECs, and macrophages. These results indicate that nonspecific peptide degradation depends upon both the end group chemistry of the peptide and the presence of bulky groups which can prevent the degradation of peptides conjugated to matrices, such as cross-linking peptides.

Figure 5.

Figure 5

PEG conjugation with peptides reduces degradation rates. (A) Peptides with different terminal chemistries were synthesized with azides on either their N- or C-terminus a portion were modified with (PEG)12-DBCO. (B). Both the azide- and PEG-modified peptides were incubated with hMSCs for 48 h, and peptides featuring PEG conjugations showed less degradation across all N-terminal chemistries.

Effects of RGD Chemistry on Cell Behavior in Hydrogels

We next sought to better understand how the presence of fast- and slow-degrading RGD sequences influenced cell behavior and peptide degradation when it was covalently coupled to a hydrogel. To do this, we made hydrogels with both “fast”-degrading NH2-GRGDS peptides and slow-degrading Ac-βA-GRGDS peptides. As a positive control, we used a cyclic RGD peptide (cRGD), which does not have a terminus and is not susceptible to degradation by exopeptidases. We also included a negative control, which consisted of gels without any RGD peptides. To better understand the effects of RGD stability on cell morphology (Figure 6), we quantified hMSC spreading at Day 7 in hydrogels with cyclic RGD, slow-degrading Ac-βA-GRGDS, fast-degrading NH2-GRGDS and gels with no RGD peptides (Figures 6E and S9). We found that hMSCs in the cRGD gels had the most spreading (769 ± 119 μm2), followed by Ac-βA-GRGDS (746 ± 149 μm2), NH2-GRGDS (626 ± 193 μm2), and gels without RGD (400 ± 91 μm2). Hydrogels with cRGD and Ac-βA-GRGDS had more spreading than gels with either NH2-GRGDS or no RGD, although the differences with the NH2-GRGDS were not statistically significant (p > 0.05). We also found that viability within gels was primarily dependent upon the presence of RGD; however, this varied by cell type (Figure S10). Gels containing the cyclic RGD peptide had the greatest viability across all cell types, which was also seen in Live/Dead staining (Figures S11–S13). This could be due to both the inability of cyclic peptides to undergo exopeptidase degradation or the beneficial effect that the cyclization of RGD sequences can have on adhesion. Finally, the presence of different RGD ligands did not appear to significantly influence the macroscopic degradation of the hydrogels (Figure S14).

Figure 6.

Figure 6

RGD is required for cell spreading and viability within hydrogels. (A) Ac-βA-GRGDS, (B) NH2-GRGDS, (C) cyclic RGDS (cRGD), and (D) no added RGDS. (E) hMSC spreading was increased in hydrogels which were functionalized with RGD peptides. Red is actin and blue is the nucleus. Scale bar is 100 μm and * indicates p < 0.05, *** indicates p < 0.001 by Tukey’s post hoc test.

Conclusions

In conclusion, we synthesized a series of peptide libraries to better understand how the proteases secreted by cells degrade peptides during cell culture. Soluble peptides with canonical termini, such as an N-terminal amine, were rapidly degraded by two cell types found in most tissues, endothelial cells and macrophages, and one commonly used in biomedical applications, hMSCs, irrespective of the N-terminal amino acid. Peptide degradation with N-terminal amines and C-terminal carboxylic acids was also found in cells cultured in hydrogels with multiple peptide sequences. We found that simple modifications to the protein termini could greatly slow down or abolish the nonspecific degradation of soluble peptides by cells on TCP or cells within a hydrogel. Finally, we found that RGD was important for cell spreading and viability within hydrogel matrices.

Acknowledgments

We would like to acknowledge our funding sources, the NIH (1R21GM143593-01) and NSF (award 2138723). We are grateful to the lab of Lesley Chow for the use of their preparative high-performance liquid chromatography.

Supporting Information Available

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsbiomaterials.4c00736.

  • Additional degradation data comparing peptide degradation by the donor, concentrations, peptide sequence, or PEG functionalization; biological data including fluorescence microscopy, quantification of viability and proliferation, and live/dead imaging; LCMS spectra for all peptides used in this study; and statistical analyses (PDF)

The authors declare no competing financial interest.

Supplementary Material

ab4c00736_si_001.pdf (85.8MB, pdf)

References

  1. Rosales A. M.; Anseth K. S. The design of reversible hydrogels to capture extracellular matrix dynamics. Nat. Rev. Mater. 2016, 1 (2), 15012–15015. 10.1038/natrevmats.2015.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Liaw C. Y.; Ji S.; Guvendiren M. Engineering 3D hydrogels for personalized in vitro human tissue models. Adv. Healthcare Mater. 2018, 7 (4), 1701165. 10.1002/adhm.201701165. [DOI] [PubMed] [Google Scholar]
  3. Ligorio C.; Mata A. Synthetic extracellular matrices with function-encoding peptides. Nat. Rev. Bioeng. 2023, 1, 518–536. 10.1038/s44222-023-00055-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ferreira S. A.; Motwani M. S.; Faull P. A.; Seymour A. J.; Yu T. T.; Enayati M.; Taheem D. K.; Salzlechner C.; Haghighi T.; Kania E. M.; Oommen O. P.; Ahmed T.; Loaiza S.; Parzych K.; Dazzi F.; Varghese O. P.; Festy F.; Grigoriadis A. E.; Auner H. W.; Snijders A. P.; Bozec L.; Gentleman E. Bi-directional cell-pericellular matrix interactions direct stem cell fate. Nat. Commun. 2018, 9 (1), 4049. 10.1038/s41467-018-06183-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Loebel C.; Mauck R. L.; Burdick J. A. Local nascent protein deposition and remodelling guide mesenchymal stromal cell mechanosensing and fate in three-dimensional hydrogels. Nat. Mater. 2019, 18 (8), 883–891. 10.1038/s41563-019-0307-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Pérez-Silva J. G.; Español Y.; Velasco G.; Quesada V. The Degradome database: expanding roles of mammalian proteases in life and disease. Nucleic Acids Res. 2016, 44 (D1), D351–D355. 10.1093/nar/gkv1201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kappelhoff R.; Puente X. S.; Wilson C. H.; Seth A.; López-Otín C.; Overall C. M. Overview of transcriptomic analysis of all human proteases, non-proteolytic homologs and inhibitors: organ, tissue and ovarian cancer cell line expression profiling of the human protease degradome by the CLIP-CHIP DNA microarray. Biochim. Biophys. Acta, Mol. Cell Res. 2017, 1864 (11), 2210–2219. 10.1016/j.bbamcr.2017.08.004. [DOI] [PubMed] [Google Scholar]
  8. Nabeshima K.; Inoue T.; Shimao Y.; Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol. Int. 2002, 52 (4), 255–264. 10.1046/j.1440-1827.2002.01343.x. [DOI] [PubMed] [Google Scholar]
  9. Itoh Y. MT1-MMP: A key regulator of cell migration in tissue. IUBMB Life 2006, 58 (10), 589–596. 10.1080/15216540600962818. [DOI] [PubMed] [Google Scholar]
  10. Eckhard U.; Huesgen P. F.; Schilling O.; Bellac C. L.; Butler G. S.; Cox J. H.; Dufour A.; Goebeler V.; Kappelhoff R.; auf dem Keller U.; et al. Active site specificity profiling datasets of matrix metalloproteinases (MMPs) 1, 2, 3, 7, 8, 9, 12, 13 and 14. Data Brief 2016, 7, 299–310. 10.1016/j.dib.2016.02.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Tasdemiroglu Y.; Gourdie R. G.; He J.-Q. In vivo degradation forms, anti-degradation strategies, and clinical applications of therapeutic peptides in non-infectious chronic diseases. Eur. J. Pharmacol. 2022, 932, 175192. 10.1016/j.ejphar.2022.175192. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pashuck E. T.; Duchet B. J.; Hansel C. S.; Maynard S. A.; Chow L. W.; Stevens M. M. Controlled sub-nanometer epitope spacing in a three-dimensional self-assembled peptide hydrogel. ACS Nano 2016, 10 (12), 11096–11104. 10.1021/acsnano.6b05975. [DOI] [PubMed] [Google Scholar]
  13. Huettner N.; Dargaville T. R.; Forget A. Discovering cell-adhesion peptides in tissue engineering: beyond RGD. Trends Biotechnol. 2018, 36 (4), 372–383. 10.1016/j.tibtech.2018.01.008. [DOI] [PubMed] [Google Scholar]
  14. Bellis S. L. Advantages of RGD peptides for directing cell association with biomaterials. Biomaterials 2011, 32 (18), 4205–4210. 10.1016/j.biomaterials.2011.02.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Cai L.; Dinh C. B.; Heilshorn S. C. One-pot synthesis of elastin-like polypeptide hydrogels with grafted VEGF-mimetic peptides. Biomater. Sci. 2014, 2 (5), 757–765. 10.1039/C3BM60293A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Álvarez Z.; Kolberg-Edelbrock A.; Sasselli I.; Ortega J.; Qiu R.; Syrgiannis Z.; Mirau P.; Chen F.; Chin S.; Weigand S.; et al. Bioactive scaffolds with enhanced supramolecular motion promote recovery from spinal cord injury. Science 2021, 374 (6569), 848–856. 10.1126/science.abh3602. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Lutolf M.; Lauer-Fields J.; Schmoekel H.; Metters A. T.; Weber F.; Fields G.; Hubbell J. A. Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (9), 5413–5418. 10.1073/pnas.0737381100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hsu C. W.; Olabisi R. M.; Olmsted-Davis E. A.; Davis A. R.; West J. L. Cathepsin K-sensitive poly (ethylene glycol) hydrogels for degradation in response to bone resorption. J. Biomed. Mater. Res., Part A 2011, 98A (1), 53–62. 10.1002/jbm.a.33076. [DOI] [PubMed] [Google Scholar]
  19. Pashuck E. T.Designing Enzyme-responsive Biomaterials. In Peptide-based Biomaterials; RSC, 2020; pp 76–125. [Google Scholar]
  20. Chandrawati R. Enzyme-responsive polymer hydrogels for therapeutic delivery. Exp. Biol. Med. 2016, 241 (9), 972–979. 10.1177/1535370216647186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Zhu Y.; Shmidov Y.; Harris E. A.; Theus M. H.; Bitton R.; Matson J. B. Activating hidden signals by mimicking cryptic sites in a synthetic extracellular matrix. Nat. Commun. 2023, 14 (1), 3635. 10.1038/s41467-023-39349-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Gentilucci L.; De Marco R.; Cerisoli L. Chemical modifications designed to improve peptide stability: incorporation of non-natural amino acids, pseudo-peptide bonds, and cyclization. Curr. Pharm. Des. 2010, 16 (28), 3185–3203. 10.2174/138161210793292555. [DOI] [PubMed] [Google Scholar]
  23. Cooper B. M.; Iegre J.; O’Donovan D. H.; Ölwegård Halvarsson M.; Spring D. R. Peptides as a platform for targeted therapeutics for cancer: Peptide-drug conjugates (PDCs). Chem. Soc. Rev. 2021, 50 (3), 1480–1494. 10.1039/d0cs00556h. [DOI] [PubMed] [Google Scholar]
  24. Marciano Y.; Nayeem N.; Dave D.; Ulijn R. V.; Contel M. N-Acetylation of Biodegradable Supramolecular Peptide Nanofilaments Selectively Enhances Their Proteolytic Stability for Targeted Delivery of Gold-Based Anticancer Agents. ACS Biomater. Sci. Eng. 2023, 9, 3379–3389. 10.1021/acsbiomaterials.3c00312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Arnesen T.; Van Damme P.; Polevoda B.; Helsens K.; Evjenth R.; Colaert N.; Varhaug J. E.; Vandekerckhove J.; Lillehaug J. R.; Sherman F.; et al. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (20), 8157–8162. 10.1073/pnas.0901931106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Powell M. F.; Stewart T.; Otvos Jr L.; Urge L.; Gaeta F. C.; Sette A.; Arrhenius T.; Thomson D.; Soda K.; Colon S. M. Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum. Pharm. Res. 1993, 10, 1268–1273. 10.1023/a:1018953309913. [DOI] [PubMed] [Google Scholar]
  27. Mucha A.; Drag M.; Dalton J. P.; Kafarski P. Metallo-aminopeptidase inhibitors. Biochimie 2010, 92 (11), 1509–1529. 10.1016/j.biochi.2010.04.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sapio M. R.; Fricker L. D. Carboxypeptidases in disease: insights from peptidomic studies. Proteomics: Clin. Appl. 2014, 8 (5–6), 327–337. 10.1002/prca.201300090. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Sanz Y.Aminopeptidases. In Industrial Enzymes: Structure, Function and Applications; Springer, 2007; pp 243–260. [Google Scholar]
  30. Seebach D.; Beck A. K.; Bierbaum D. J. The World of β- and γ-Peptides Comprised of Homologated Proteinogenic Amino Acids and Other Components. Chem. Biodiversity 2004, 1 (8), 1111–1239. 10.1002/cbdv.200490087. [DOI] [PubMed] [Google Scholar]
  31. Di L. Strategic approaches to optimizing peptide ADME properties. AAPS J. 2015, 17, 134–143. 10.1208/s12248-014-9687-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Xiao Q.; Zhang F.; Nacev B. A.; Liu J. O.; Pei D. Protein N-terminal processing: substrate specificity of Escherichia coli and human methionine aminopeptidases. Biochemistry 2010, 49 (26), 5588–5599. 10.1021/bi1005464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Böttger R.; Hoffmann R.; Knappe D. Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum. PLoS One 2017, 12 (6), e0178943 10.1371/journal.pone.0178943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rezania A.; Healy K. E. The effect of peptide surface density on mineralization of a matrix deposited by osteogenic cells. J. Biomed. Mater. Res. 2000, 52 (4), 595–600. . [DOI] [PubMed] [Google Scholar]
  35. Pfaff M.; Tangemann K.; Müller B.; Gurrath M.; Müller G.; Kessler H.; Timpl R.; Engel J. Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem. 1994, 269 (32), 20233–20238. 10.1016/S0021-9258(17)31981-6. [DOI] [PubMed] [Google Scholar]
  36. Furka A.; Sebestyén F.; Asgedom M.; Dibó G. General method for rapid synthesis of multicomponent peptide mixtures. Int. J. Pept. Protein Res. 1991, 37 (6), 487–493. 10.1111/j.1399-3011.1991.tb00765.x. [DOI] [PubMed] [Google Scholar]
  37. Chen L.; Lin Y.-L.; Peng G.; Li F. Structural basis for multifunctional roles of mammalian aminopeptidase N. Proc. Natl. Acad. Sci. U.S.A. 2012, 109 (44), 17966–17971. 10.1073/pnas.1210123109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Silva G. A.; Czeisler C.; Niece K. L.; Beniash E.; Harrington D. A.; Kessler J. A.; Stupp S. I. Selective differentiation of neural progenitor cells by high-epitope density nanofibers. Science 2004, 303 (5662), 1352–1355. 10.1126/science.1093783. [DOI] [PubMed] [Google Scholar]
  39. Seims K. B.; Hunt N. K.; Chow L. W. Strategies to control or mimic growth factor activity for bone, cartilage, and osteochondral tissue engineering. Bioconjugate Chem. 2021, 32 (5), 861–878. 10.1021/acs.bioconjchem.1c00090. [DOI] [PubMed] [Google Scholar]
  40. Amer L. D.; Bryant S. J. The in vitro and in vivo response to MMP-sensitive poly (ethylene glycol) hydrogels. Ann. Biomed. Eng. 2016, 44 (6), 1959–1969. 10.1007/s10439-016-1608-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Darling N. J.; Hung Y.-S.; Sharma S.; Segura T. Controlling the kinetics of thiol-maleimide Michael-type addition gelation kinetics for the generation of homogenous poly (ethylene glycol) hydrogels. Biomaterials 2016, 101, 199–206. 10.1016/j.biomaterials.2016.05.053. [DOI] [PubMed] [Google Scholar]
  42. DeForest C. A.; Polizzotti B. D.; Anseth K. S. Sequential click reactions for synthesizing and patterning three-dimensional cell microenvironments. Nat. Mater. 2009, 8 (8), 659–664. 10.1038/nmat2473. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

ab4c00736_si_001.pdf (85.8MB, pdf)

Articles from ACS Biomaterials Science & Engineering are provided here courtesy of American Chemical Society

RESOURCES